**11.6 Liposome as anti-infective agents**

Amphotericin B (ambisome) is now available in liposome based formulation has passed all the clinical trials. Liposomal Amphotericin B targets liver and spleen by passively and reduces renal toxicity at normal dose and toxicity appears back when given at higher dose [110, 111].

#### **11.7 Liposome in tumor therapy**

Long therapy treatment with anticancer drugs gives several toxic effects but liposomal for tumor cells showed less side effects. Reported methods showed liposomes targets to tumor cells and circulate for longer time period with enhanced vascular permeability [112, 113]. In the year 1995, Doxil which is Doxorubicin PEGylated liposomes, for intravenous administration prepared by stealth technology was approved for hematological tumors [5, 6]. Caelyx and myocet are other liposome preparations for same doxorubicin used for advanced breast cancer [114–116].
